INNOVIVA,INC. (NASDAQ:INVA) Files An 8-K Other Events

INNOVIVA,INC. (NASDAQ:INVA) Files An 8-K Other Events
Item 8.01 Other Events.

Story continues below

On September19, 2017, GlaxoSmithKline plc (“GSK”) and Innoviva,Inc. (Innoviva) distributed a press release announced positive headline results from the phase III InforMing the PAthway of COPD Treatment (IMPACT) study of Trelegy Ellipta, the first and only once-daily single inhaler triple therapy comprising an inhaled corticosteroid (ICS), long-acting muscarinic antagonist (LAMA) and long-action beta agonist (LABA) approved by the U.S. Food and Drug Administration (“FDA”).

Trelegy Ellipta (fluticasone furoate/umeclidinium/vilanterol, FF/UMEC/VI) is approved by the FDA for the long-term, once-daily, maintenance treatment of patients with chronic obstructive pulmonary disease, including chronic bronchitis and/or emphysema, who are on a fixed-dose combination of fluticasone furoate and vilanterol for airflow obstruction and reducing exacerbations, in whom additional treatment of airflow obstruction is desired or patients who are on umeclidinium and a fixed-dose combination of fluticasone furoate and vilanterol.

The press release is filed as Exhibit99.1 to this report and is incorporated herein by reference.

Item 9.01.Financial Statements and Exhibits.

(d)Exhibits

99.1

Press Release dated September19, 2017


Innoviva, Inc. Exhibit
EX-99.1 2 a17-22274_1ex99d1.htm EX-99.1 Exhibit 99.1   PRESS RELEASE               Issued: 19 September 2017,…
To view the full exhibit click here

About INNOVIVA,INC. (NASDAQ:INVA)

Innoviva, Inc., formerly Theravance, Inc., focuses on bringing new medicines to patients in areas of unmet need. The Company is engaged in the development, commercialization and financial management of bio-pharmaceuticals. Its portfolio focuses on the respiratory assets partnered with Glaxo Group Limited (GSK), including RELVAR/BREO ELLIPTA (fluticasone furoate/vilanterol (FF/VI)) and ANORO ELLIPTA (umeclidinium bromide/vilanterol (UMEC/VI)). It operates in providing capital return to stockholders by maximizing the potential value of its respiratory assets partnered with GSK segment. RELVAR/BREO is a once-a-day combination inhaled respiratory medicine consisting of VI, a LABA and FF, an inhaled corticosteroid (FF/VI) delivered via the ELLIPTA dry powder inhaler. ANORO ELLIPTA is a dual bronchodilator consisting of UMEC, a long-acting muscarinic antagonist (LAMA) and VI, a LABA for the treatment of chronic obstructive pulmonary diseases (COPD).

An ad to help with our costs